Treatment of TP53-mutated myelodysplastic syndrome and acute myeloid leukemia with lowintensity metronomic decitabine and venetoclax - PubMed
5 hours ago
- #TP53-mutated myeloid malignancies
- #venetoclax
- #metronomic decitabine
- Standard treatment for elderly/unfit AML patients is venetoclax combined with hypomethylating agents (HMAs).
- A metronomic schedule of low-dose decitabine and venetoclax was developed to reduce hospitalizations during COVID.
- Study analyzed 40 patients with TP53-mutated MDS and AML; median age 76.5, 82% had bi-allelic TP53 mutations.
- Overall response rate: AML (CR+CRi) 70%, MDS (CR+mCR) 57%, with median OS of 11.3 months for the cohort.
- Transfusion independence achieved in 58%; low toxicity profile with no therapy-related fatalities and 7.5% 100-day mortality.